• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化生性乳腺癌的分子特征:三阴性乳腺癌的一种罕见亚型

Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.

作者信息

González-Martínez Silvia, Pérez-Mies Belén, Carretero-Barrio Irene, Palacios-Berraquero María Luisa, Perez-García José, Cortés Javier, Palacios José

机构信息

Clinical Researcher, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.

Pathology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.

出版信息

Cancers (Basel). 2020 Jul 8;12(7):1832. doi: 10.3390/cancers12071832.

DOI:10.3390/cancers12071832
PMID:32650408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7408634/
Abstract

Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent invasive carcinomas that display differentiation of the neoplastic epithelium towards squamous cells and/or mesenchymal-type elements. Most MBC have a triple negative phenotype and poor prognosis. Thus, MBC have worse survival rates than other invasive breast carcinomas, including other triple negative breast carcinomas (TNBC). In this study, we reviewed the molecular features of MBC, pointing out the differences among subtypes. The most frequently mutated genes in MBC were and . Additionally, mutations in the other genes of the PI3K/AKT pathway indicated its importance in the pathogenesis of MBC. Regarding copy number variations (CNVs), was the most frequently amplified gene, and the most frequent gene loss affected the locus. Furthermore, the pattern of mutations and CNVs of MBC differed from those reported in other TNBC. However, the molecular profile of MBC was not homogeneous among histological subtypes, being the alterations in the PI3K pathway most frequent in spindle cell carcinomas. Transcriptomic studies have demonstrated an epithelial to mesenchymal program activation and the enrichment of stemness genes in most MBC. In addition, current studies are attempting to define the immune microenvironment of these tumors. In conclusion, due to specific molecular features, MBC have a different clinical behavior from other types of TNBC, being more resistant to standard chemotherapy. For this reason, new therapeutic approaches based on tumor molecular characteristics are needed to treat MBC.

摘要

化生性乳腺癌(MBC)是一组异质性的罕见浸润性癌,其肿瘤上皮向鳞状细胞和/或间充质样成分分化。大多数MBC具有三阴性表型且预后较差。因此,MBC的生存率低于其他浸润性乳腺癌,包括其他三阴性乳腺癌(TNBC)。在本研究中,我们回顾了MBC的分子特征,指出了各亚型之间的差异。MBC中最常发生突变的基因是 和 。此外,PI3K/AKT途径其他基因的突变表明其在MBC发病机制中的重要性。关于拷贝数变异(CNV), 是最常扩增的基因,最常见的基因缺失影响 位点。此外,MBC的突变和CNV模式与其他TNBC报道的不同。然而,MBC的分子特征在组织学亚型中并不一致,PI3K途径的改变在梭形细胞癌中最为常见。转录组学研究表明,大多数MBC中存在上皮-间充质程序激活和干性基因富集。此外,目前的研究正在尝试定义这些肿瘤的免疫微环境。总之,由于特定的分子特征,MBC具有与其他类型TNBC不同的临床行为,对标准化疗更具抗性。因此,需要基于肿瘤分子特征的新治疗方法来治疗MBC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5b5/7408634/ea18f1bbf968/cancers-12-01832-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5b5/7408634/ea18f1bbf968/cancers-12-01832-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5b5/7408634/ea18f1bbf968/cancers-12-01832-g001.jpg

相似文献

1
Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.化生性乳腺癌的分子特征:三阴性乳腺癌的一种罕见亚型
Cancers (Basel). 2020 Jul 8;12(7):1832. doi: 10.3390/cancers12071832.
2
Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.乳腺化生性癌比三阴性乳腺癌更具侵袭性:单中心研究及文献复习。
Clin Breast Cancer. 2017 Aug;17(5):382-391. doi: 10.1016/j.clbc.2017.04.009. Epub 2017 Apr 26.
3
Analysis of clinicopathological characteristics and prognostic factors in 54 metaplastic breast carcinoma patients from northwest China.中国西北54例化生性乳腺癌患者的临床病理特征及预后因素分析
Cytojournal. 2024 Sep 18;21:31. doi: 10.25259/Cytojournal_15_2024. eCollection 2024.
4
Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.对化生性乳腺癌进行基因组分析揭示了遗传异质性及其与导管癌的关系。
Mod Pathol. 2018 Nov;31(11):1661-1674. doi: 10.1038/s41379-018-0081-z. Epub 2018 Jun 26.
5
Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected].化生性乳腺癌表现出基因组和转录组的异质性[已修正]。
Mod Pathol. 2015 Mar;28(3):340-51. doi: 10.1038/modpathol.2014.142. Epub 2014 Nov 21.
6
Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.上皮间质转化与肿瘤发生中的免疫应答。
Int J Mol Sci. 2021 Jul 9;22(14):7398. doi: 10.3390/ijms22147398.
7
Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.三阴性乳腺癌伴化生性和浸润性导管癌的预后分析比较。
J Clin Pathol. 2019 Jun;72(6):418-424. doi: 10.1136/jclinpath-2018-205544. Epub 2019 Mar 14.
8
Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.探讨化生性乳腺癌的表型和分子特征及其预后意义。
J Pathol. 2019 Feb;247(2):214-227. doi: 10.1002/path.5184. Epub 2018 Dec 20.
9
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast.乳腺化生性癌中的基因组和转录组异质性。
NPJ Breast Cancer. 2017 Dec 1;3:48. doi: 10.1038/s41523-017-0048-0. eCollection 2017.
10
Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors.癌肉瘤型乳腺癌病理亚型的定量蛋白质组学全景及其与三阴性肿瘤的关系。
Nat Commun. 2020 Apr 7;11(1):1723. doi: 10.1038/s41467-020-15283-z.

引用本文的文献

1
Translational Aspects in Metaplastic Breast Carcinoma.化生性乳腺癌的转化研究方面
Cancers (Basel). 2024 Apr 7;16(7):1433. doi: 10.3390/cancers16071433.
2
Intragenic .E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors.4331例实体瘤中的基因内E1E8融合(EGFRvIII)
Cancers (Basel). 2023 Dec 19;16(1):6. doi: 10.3390/cancers16010006.
3
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades.三阴性乳腺癌:二十年间从无到有出现多种治疗靶点

本文引用的文献

1
The Play of Promoter Mutations.启动子突变的游戏。
Cells. 2020 Mar 19;9(3):749. doi: 10.3390/cells9030749.
2
Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.乳腺化生性梭形细胞癌的分子特征分析揭示了潜在的可靶向生物标志物。
Clin Breast Cancer. 2020 Aug;20(4):326-331.e1. doi: 10.1016/j.clbc.2020.02.008. Epub 2020 Feb 27.
3
Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.广泛骨分化的化生性乳腺癌的全外显子组分析。
Front Oncol. 2023 Nov 9;13:1244781. doi: 10.3389/fonc.2023.1244781. eCollection 2023.
4
Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer.免疫疗法联合化疗用于复发性化生性乳腺癌
Onco Targets Ther. 2023 Oct 30;16:885-890. doi: 10.2147/OTT.S435958. eCollection 2023.
5
Development and validation of competitive risk model for older women with metaplastic breast cancer.发展和验证老年女性伴间变性乳腺癌的竞争风险模型。
BMC Womens Health. 2023 Jul 14;23(1):374. doi: 10.1186/s12905-023-02513-x.
6
Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer.三阴性乳腺癌患者新辅助化疗期间肿瘤进展及生存结局的预测。
Korean J Radiol. 2023 Jul;24(7):626-639. doi: 10.3348/kjr.2022.0974.
7
Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape.美国人群中的化生性乳腺癌:种族差异、辅助放化疗的生存获益以及基于基因组图谱的未来个性化治疗
Cancers (Basel). 2023 May 28;15(11):2954. doi: 10.3390/cancers15112954.
8
Metaplastic Breast Cancer: Current Understanding and Future Directions.化生性乳腺癌:当前认识与未来方向
Clin Breast Cancer. 2023 Dec;23(8):775-783. doi: 10.1016/j.clbc.2023.04.004. Epub 2023 Apr 19.
9
The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.混合亚型比其他组织学亚型预后更差:217 例化生性乳腺癌患者的回顾性分析。
Breast Cancer Res Treat. 2023 Jul;200(1):23-36. doi: 10.1007/s10549-023-06945-9. Epub 2023 May 9.
10
Multimodality imaging and histopathology of metaplastic breast cancer.多模态影像学与癌肉瘤型乳腺癌的组织病理学。
Diagn Interv Radiol. 2023 Jan 31;29(1):59-67. doi: 10.4274/dir.2022.221363. Epub 2023 Jan 12.
Histopathology. 2020 Aug;77(2):321-326. doi: 10.1111/his.14088.
4
Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? A series of 39 patients.乳腺鳞状细胞癌,是否存在两种具有不同预后的实体?一系列 39 例患者。
Breast Cancer Res Treat. 2020 Feb;180(1):87-95. doi: 10.1007/s10549-020-05525-5. Epub 2020 Jan 22.
5
Somatic Mutation of (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers.(H1047R)的体细胞突变是犬乳腺肿瘤以及人类乳腺癌中常见的驱动突变热点。
Cancers (Basel). 2019 Dec 12;11(12):2006. doi: 10.3390/cancers11122006.
6
Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.化生性乳腺癌的突变和免疫特征分析:与生存的相关性。
PLoS One. 2019 Nov 6;14(11):e0224726. doi: 10.1371/journal.pone.0224726. eCollection 2019.
7
Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination.化疗难治性转移性化生性乳腺癌对紫杉醇-免疫疗法联合治疗的完全缓解
Am J Case Rep. 2019 Nov 6;20:1630-1635. doi: 10.12659/AJCR.918770.
8
Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.生长因子受体网络和干性通路的途径活性分析可区分癌肉瘤样乳腺癌的组织学亚型。
BMC Cancer. 2019 Sep 5;19(1):881. doi: 10.1186/s12885-019-6052-z.
9
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant.新辅助 Talazoparib 治疗携致病性种系突变的可手术乳腺癌患者。
J Clin Oncol. 2020 Feb 10;38(5):388-394. doi: 10.1200/JCO.19.01304. Epub 2019 Aug 28.
10
Metaplastic breast carcinoma: Current therapeutic approaches and novel targeted therapies.化生性乳腺癌:当前的治疗方法和新的靶向治疗。
Breast J. 2019 Nov;25(6):1192-1197. doi: 10.1111/tbj.13416. Epub 2019 Jun 27.